REMEDIUM CAPITAL PARTNERS LLC
Q1 2026 Form 13-F

FORT LAUDERDALE, DELAWARE
CIK 0002104501 · CRD 340302 · SEC-registered investment adviser
$281.2M Reported Value Total

REMEDIUM CAPITAL PARTNERS reports 1 total accounts under management (AUM). There are 1 discretionary accounts valued at $155,000,000, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Source: Form ADV filed 2026-08-20
Reported value
$281.2M
Quarter over quarter
+35.5%
Holdings
6
Top-10 concentration
100.0%

Key People

Form ADV owners & control persons
Chad Christopher Hellmann
CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2026 13F record

Q1 2026 13F filing summary

Q1 2026 Form 13F portfolio summary
Period of report March 31, 2026
Filed May 13, 2026
Form 13F-HR
Reported value $281.2M
Positions 6
Change in reported value +65.2%
New positions 0
Exited positions 0
Position turnover 0.0%
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 13, 2026
6 $273.6M
Q2 2026 13F
Filed Aug 7, 2026
6 $451.6M
Q1 2026 13F
Filed May 13, 2026
6 $281.2M
Q4 2025 13F
Filed Feb 12, 2026
6 $170.2M

Top 6 holdings · Q1 2026

Largest Q1 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 ORKA Oruka Therapeutics Inc $76.8M 27.31%
2 SYRE Spyre Therapeutics Inc $73.5M 26.13%
3 GLTO Damora Therapeutics Inc $53.0M 18.84%
4 APGE Apogee Therapeutics Inc $49.1M 17.47%
5 JBIO Jade Biosciences Inc $22.2M 7.88%
6 CBIO Crescent Biopharma Inc $6.6M 2.36%

Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings